The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Bevacizumab (B) + bi-weekly capecitabine (C) and oxaliplatin (O) (XELOX2) or FOLFOX4 in first-line treatment of metastatic colorectal cancer (mCRC): Final results of a multicenter randomized phase II trial of the Gruppo Oncologico dell’Italia Meridionale (GOIM protocol 2802).
 
Evaristo Maiello
Travel, Accommodations, Expenses - Merck Serono
 
Gabriele Di Maggio
No Relationships to Disclose
 
Stefano Sergio Cordio
No Relationships to Disclose
 
Saverio Cinieri
No Relationships to Disclose
 
Francesco Giuliani
No Relationships to Disclose
 
Salvatore Pisconti
No Relationships to Disclose
 
Antonio Rinaldi
No Relationships to Disclose
 
Antonio Febbraro
No Relationships to Disclose
 
Tiziana Pia Latiano
No Relationships to Disclose
 
Michele Aieta
No Relationships to Disclose
 
Daniele Rizzi
No Relationships to Disclose
 
Massimo Di Maio
Honoraria - AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; Merck Sharp & Dohme
Consulting or Advisory Role - AstraZeneca; Janssen; Lilly
Research Funding - Tesaro
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Janssen; Merck Sharp & Dohme; Novartis
 
Giuseppe Colucci
No Relationships to Disclose
 
Roberto Bordonaro
Honoraria - AstraZeneca; Novartis
Consulting or Advisory Role - Novartis
Speakers' Bureau - AstraZeneca; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; Bayer